Using natural compounds to target KRAS mutated non-small cell lung cancer

This article was originally published here

Curr Med Chem. 2021 Feb 28. doi: 10.2174/0929867328666210301105856. Online ahead of print.

ABSTRACT

Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant-based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and down-stream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

PMID:33645474 | DOI:10.2174/0929867328666210301105856